Tomotherapy Incorporated (MM) (NASDAQ:TTPY)
Historical Stock Chart
From Jun 2019 to Jun 2024
TomoTherapy Incorporated (NASDAQ:
TTPY) announced today that the University
Hospital of Lausanne (CHUV) has begun treating patients with the
TomoTherapy® Hi-Art® treatment
system, the first to be installed in Switzerland.
“We are pleased to work with the CHUV to make
this new weapon in the fight against cancer available to Swiss patients,”
said Rik Van den Neste, M.D., director of European sales for
TomoTherapy. “By implementing the TomoTherapy
platform, the CHUV demonstrates its leadership and commitment to
providing access to new strategies for care.”
The CHUV ranks 14th among 400 institutions
affiliated with the European Organisation
for Research and Treatment of Cancer (EORTC), which aims to reduce
the time lapse between the discovery of new technologies and the
implementation of their therapeutic benefit for patients with cancer.
The Hospital provides holistic care for a wide range of cancer patients
and looks forward to strengthening this approach with the unique
capabilities of the Hi-Art treatment system.
Said Professor René-Olivier Mirimanoff, M.D.,
head of the Radio-Oncology department, “TomoTherapy
helps us better target the tumour to be irradiated and preserve healthy
tissue located in the vicinity. Integrated CT imaging allows for the
scanning of patients before each treatment, which helps ensure proper
positioning.”
Dr Raphaël Moeckli, Ph.D., head physicist,
added, “The system’s
delivery pattern makes it possible to ‘paint’
the dose onto the tumour volume, from 360 degrees. These features open
new possibilities for minimizing the side effects of treatment, and for
treating types of cancer that were previously difficult to irradiate
because of nearby critical structures.”
The Radio-Oncology Department, managed by the CHUV, recently hosted a
ceremony to introduce this state-of-the-art technology that integrates
CT image guidance and helical intensity-modulated radiation therapy for
greater accuracy and precision in the treatment of cancer. The event
included a scientific symposium attended by radiation oncologists,
medical physicists and therapists from across Switzerland and a public
conference attended by more than 100 local journalists and patient group
members.
About the CHUV
CHUV is one of the 5 major university hospitals in Switzerland. It
provides from primary to tertiary care in all domains of medicine, and
one of its major focuses is cancer. Many doctors and scientists are
involved in basic, translational and clinical research in cancer
medicine, which contributes to its international visibility. A number of
clinicians are currently involved in national and international
cooperative cancer research groups, including SAKK, EORTC, and hold
officer’s positions or have a leading role as
principal investigators of international trials. The department of
Radiation Oncology has an active role and has contributed to a number of
major international studies in various fields of oncology and has a
leading position in Switzerland
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the
TomoTherapy® Hi-Art®
treatment system, an advanced radiation therapy system for the treatment
of a wide variety of cancers. The Hi-Art treatment system
combines integrated CT imaging with conformal radiation therapy to
deliver sophisticated radiation treatments with speed and precision
while reducing radiation exposure to surrounding healthy tissue. The
company completed its initial public offering in May 2007 and its stock
is traded on the NASDAQ Global Market under the symbol TTPY. To learn
more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.
©2007 TomoTherapy Incorporated. All rights
reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among
trademarks, service marks or registered trademarks of TomoTherapy
Incorporated.